Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO -- Ignore unavailable to you. Want to Upgrade?

To: jeffbas who wrote (201)	12/12/1999 10:50:00 AM
From: Mike McFarland	Read Replies (2) \| Respond to of 438

Here is what I had scrawled down on that--I think this is not new news: In original trials 15-20% of patients had a "dramatic" response...meaning greater than a 50% reduction in tumors. There is a mart-1/gp100 (my notes are not very good here) phase I/II ongoing which is "in the middle of the trial" and "results are coming next year". You could obviously snag that off the replay as well. Where I was most impressed with Gail was listening in on the conversations between presentations. Oh, here is something I scrawled down for Rick: The slide with the small molecules... Anti-Angiogenesis> Proteins, Gene Therapy, Small Molecules... and under small molecules>> Growth Factors, Extracellular matrix, Cell Proliferation --and all that was listed as "research stage" When I asked about patenting transcripts found with SAGE I got the expected answer--sorry, no easter eggs, and you can get that off the replay as well. Oh, she might also said something about not worrying so much about the quarterly financials...and that cash is good through 2001--the fellow from Corixa made that point as well, and Parker from TGEN--they all want to keep investors calm about that little cash item that everybody seems to sweat, some quarters just burn a lot more than others.